Plain-English translation of NCT06954480 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new cancer medication called Datopotamab deruxtecan, which works by targeting cancer cells and delivering medicine directly to them. The study will compare whether adding an immune-boosting drug called to this treatment helps patients live longer without their cancer growing, compared to using the cancer medication alone.
Triple-negative breast cancer is especially challenging because it grows quickly and has fewer treatment options than other breast cancers. Early research suggests that combining a targeted cancer drug with a medication that awakens the body's immune system might work better together than either one alone.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be randomly assigned to receive either the new cancer medication alone or combined with the immune-boosting drug. You will receive these medications on a regular schedule (typically intravenously) and visit the clinic for infusions, blood tests, and scans to monitor how your cancer responds. The treatment continues unless your cancer grows, you experience unacceptable side effects, or you decide to stop — and researchers will track your health and quality of life throughout the study.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
United Kingdom